Stocksigma LogoStocksigma Logo

Aptus Pharma Reports Strong H1 Performance and Approves Preferential Equity Issue

For the half year ended 30th Sep'26, Aptus Pharma reported standalone revenue from operations of INR 48.92 cr, up 240% YoY from INR 14.38 cr

Aptus Pharma Reports Strong H1 Performance and Approves Preferential Equity Issue

Aptus Pharma Ltd 路 Outcome 路 21 Oct 2026, 12:30 am

Aptus Pharma Reports Strong H1 Performance and Approves Preferential Equity Issue For the half year ended 30th Sep'26, Aptus Pharma reported standalone revenue from operations of INR 48.92 cr, up 240% YoY from INR 14.38 cr. Profit after tax rose 191% YoY to INR 5.08 cr versus INR 1.75 cr, with half-year EPS at INR 2.96. Shareholders approved a preferential issue of 16.03 lakh equity shares at INR 280 per share (including INR 270 premium), raising INR 44.88 cr, pending BSE in-principle approval. The company targets 46% pan-India geographic coverage by Mar'27.

Original exchange filing (PDF)

More announcements from Aptus Pharma Ltd

All Aptus Pharma Ltd announcements